2Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. J Natl Cancer Inst, 2000,92(3) :205-216.
3Kosmidis P. Chemotherapy in NSCLC: histrocial review [J].Lung Cancer, 2002,38(Suppl 3):S19-S22.
4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncol, 2000,18(10): 2095-2103.
5Fossella DV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy regimens [J]. J Clin Oncol,2000,18(12) :2354-2362.
6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21 (12): 2237-2246.
7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer [J]. JAMA, 2003,290(16) :2149-2158.
8Lynch, T, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying resensiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med,2004,350(21 ): 2129-2139.
9Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [J]. Science, 2004,304(5676): 1497-1500.
10Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan [J]. Clin Cancer Res, 2004, 10(24) :8195-8203.
